What is motixafortide used for?

It helps move (mobilize) hematopoietic stem cells from the bone marrow into the blood so they can be collected before an autologous stem-cell transplant in multiple myeloma. It is not a general peptide supplement.

It is a single weight-based subcutaneous injection given roughly 10-14 hours before apheresis, alongside G-CSF, in a monitored clinical setting.

What are the main side effects?

Injection-site reactions (pain, redness, itching) and transient systemic reactions such as flushing are most common; serious anaphylactoid-type reactions can occur, so premedication and monitoring are used.

How does it differ from plerixafor?

Both are CXCR4 antagonists used with G-CSF for stem-cell mobilization; they differ in structure, dosing, and administration details, and the choice is made by the transplant team.

EMA-approvedaka Aphexda, BL-8040

Motixafortide — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Motixafortide (also known as Aphexda) is a peptide catalogued under Therapeutic Peptides (CXCR4 antagonist). It is described as: CXCR4. Documented context: Stem cell mobilization multiple myeloma. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Motixafortide?

Motixafortide (brand name Aphexda) is a synthetic peptide antagonist of the CXCR4 chemokine receptor. The US FDA approved it in September 2023, in combination with granulocyte colony-stimulating factor (G-CSF/filgrastim), to mobilize hematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma.

The evidence is pivotal-trial grade in humans: approval was based on the randomized, double-blind, placebo-controlled phase 3 GENESIS trial.

How does Motixafortide work?

Motixafortide blocks the CXCR4 receptor, disrupting the CXCR4/CXCL12 (SDF-1) axis that anchors hematopoietic stem cells in the bone marrow.

This releases stem cells into the peripheral blood so they can be collected by apheresis, and its effect is complementary to G-CSF.

What does the research say about Motixafortide?

In the pivotal phase 3 GENESIS trial, motixafortide plus G-CSF enabled significantly more multiple myeloma patients to collect the target number of CD34+ stem cells, and to do so in fewer apheresis sessions, compared with placebo plus G-CSF. ^[1]
Comparative reviews position motixafortide plus G-CSF as an option that can reduce the number of apheresis procedures relative to G-CSF-based mobilization, though it is used within specialist transplant protocols. ^[3]
Its mechanism targets the CXCR4/CXCL12 axis, a pathway central to stem-cell retention in the marrow and to the broader biology of multiple myeloma. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial — Crees ZD et al., Nature Medicine 2023. (Randomized double-blind placebo-controlled phase 3 trial (GENESIS))
[2] Motixafortide: First Approval — Hoy SM et al., Drugs 2023. (Drug-approval review)
[3] A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection — Dietz L et al., Journal of Oncology Pharmacy Practice 2024. (Comparative narrative review)
[4] Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM) — Du J et al., Cell Communication and Signaling 2024. (Mechanistic/oncobiology review)
[5] Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma — Close S et al., Transfusion 2026. (Comparative observational analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Motixafortide is given as a single weight-based subcutaneous injection about 10-14 hours before apheresis, together with G-CSF, as part of a stem-cell mobilization protocol.

This is context only and not a dosing recommendation; the actual regimen, premedication, and monitoring are determined by the transplant team per the approved label.

Side effects & safety profile

The most common adverse reactions are injection-site reactions (pain, erythema, pruritus) and transient systemic reactions such as flushing, and reactions consistent with histamine release; premedication (for example with an antihistamine, and often an analgesic/antipyretic) is used to reduce these.

Serious systemic (anaphylactoid-type) reactions can occur, so motixafortide is administered in a monitored clinical setting by transplant-experienced staff prepared to manage acute reactions.

Stacking & combinations

It is used specifically in combination with G-CSF for mobilization and should not be combined with unapproved agents outside a physician-directed transplant protocol.

Finding Motixafortide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. The FDA approved motixafortide (Aphexda) in September 2023, in combination with G-CSF, to mobilize stem cells for autologous transplantation in multiple myeloma.

References

[1] Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial — Crees ZD et al., Nature Medicine 2023. PMID: 37069359. View sourceStudy: Randomized double-blind placebo-controlled phase 3 trial (GENESIS)Adding motixafortide to G-CSF allowed significantly more multiple myeloma patients to reach the CD34+ collection target in a single apheresis versus placebo plus G-CSF.
[2] Motixafortide: First Approval — Hoy SM et al., Drugs 2023. PMID: 37996648. View sourceStudy: Drug-approval reviewThis review summarizes motixafortide's mechanism, pivotal GENESIS data, safety profile, and its FDA approval for stem-cell mobilization in multiple myeloma.
[3] A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection — Dietz L et al., Journal of Oncology Pharmacy Practice 2024. PMID: 38629183. View sourceStudy: Comparative narrative reviewThe review compares motixafortide (Aphexda) and plerixafor (Mozobil) as CXCR4-based mobilization agents, including efficacy, dosing, and practical considerations.
[4] Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM) — Du J et al., Cell Communication and Signaling 2024. PMID: 38475811. View sourceStudy: Mechanistic/oncobiology reviewThis review details how chemokine receptor axes, including CXCR4/CXCL12, contribute to multiple myeloma biology and stem-cell trafficking, providing the rationale for CXCR4 antagonists.
[5] Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma — Close S et al., Transfusion 2026. PMID: 42435378. View sourceStudy: Comparative observational analysisThis real-world comparative analysis evaluates motixafortide versus plerixafor for stem-cell mobilization and collection outcomes in multiple myeloma patients.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.